As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas. Friday, Catalent and Novo Holdings—a holding company distinct from the Danish drugmaker Novo Nordisk—said the European Commission (EC) has granted “unconditional approval” to the companies’ pending transaction.
Read the full article: With Green Light from European Commission, Novo Holdings’ Proposed $16.5B Catalent Buyout Nears Close //
Source: https://www.fiercepharma.com/pharma/green-light-european-commission-novo-holdings-proposed-165b-catalent-buyout-nears-close